Core Insights - Entera Bio Ltd. reported financial results and key business updates for Q3 2024, highlighting advancements in its oral peptide and therapeutic protein development pipeline [1] Business Updates - The company is focusing on its pivotal clinical asset, EB613, an oral PTH(1-34) tablet for post-menopausal women with high-risk osteoporosis, and anticipates a significant FDA ruling in January 2025 regarding regulatory endpoints for osteoporosis drugs [2][3] - Entera's proprietary N-Tab™ platform has shown consistent results across various oral therapies, including GLP-2 and GLP-1/Glucagon tablets, with promising data presented at recent conferences [2][4][5] - The company is also developing an oral GLP-2 tablet for Short Bowel Syndrome and collaborating on an oral PTH replacement therapy for hypoparathyroidism [6][7] Financial Performance - As of September 30, 2024, Entera had cash and cash equivalents of $6.9 million, sufficient to meet projected operating requirements into Q3 2025 [7] - Research and development expenses for Q3 2024 were $1.5 million, up from $1.4 million in Q3 2023, primarily due to increased material costs for the EB613 phase 3 study [8] - General and administrative expenses rose to $1.5 million in Q3 2024 from $1.0 million in Q3 2023, driven by higher intellectual property expenses and consultancy fees [9] - The net loss for Q3 2024 was $3.0 million, consistent with the loss per share of $0.08, compared to a net loss of $2.4 million in Q3 2023 [10][16]
Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates